Evidence map›Paper›PMID 39537238›Full record

ArticleStroke and vascular neurology2025

Tenecteplase thrombolytic therapy for acute ischaemic stroke in China: a real-world, multicentre, retrospective, controlled study.

Ye Liu, Guozhi Lu, Dan Li, Guang Wu, Xiaoyu Zhou, Rongbo Qu, Yongren Fang, ZhiJiao He, Anqi Zhang, Lan Hong and 4 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke and vascular neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Thrombolytic agents, more options, more challenges.Stroke and vascular neurology · 2026
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ye Liu *Department of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0003-0648-1696
Guozhi Lu *Department of Neurology, Keshiketeng Banner Traditional Chinese Medicine Mongolian Medicine Hospitalorem Ipsum, Keshiketeng, Inner Mongolia, China.
Dan Li *Department of Neurology, Keshiketeng Banner Traditional Chinese Medicine Mongolian Medicine Hospitalorem Ipsum, Keshiketeng, Inner Mongolia, China.
Guang Wu *Department of Neurology, Nanshi Hospital Affiliated to Henan University, Nanyang, Henan, China.
Xiaoyu Zhou *Department of Neurology, Shanghai Tenth People's Hospital, Shanghai, China.ORCID http://orcid.org/0000-0002-3947-1788
Rongbo Qu *Department of Neurology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China.
Yongren FangDepartment of Neurology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, China.
ZhiJiao HeDepartment of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Anqi ZhangDepartment of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Lan HongDepartment of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-4002-4627
Kun FangDepartment of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Xin ChengDepartment of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China chengxin@fudan.edu.cn.ORCID http://orcid.org/0000-0001-7816-0547
Qiang DongDepartment of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-3874-0130
TTT-AIS CHINA collaborator

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsTenecteplase (TNK) offers logistical advantages in stroke thrombolytic therapy with its single bolus administration compared with alteplase. We aim to investigate the real-world evidence regarding its safety and effectiveness in China.

methodsWe conducted a retrospective study on patients receiving alteplase or TNK for acute ischaemic stroke (AIS) within 4.5 hours of onset between 1 March 2019 and 1 October 2023, from 18 stroke centres in China. Using propensity score matching (PSM), TNK-treated patients were matched 1:1 with alteplase-treated patients. The primary outcome was the rate of symptomatic intracranial haemorrhage (sICH) within 72 hours post-thrombolysis. Secondary outcomes comprised the rate of parenchymal haemorrhage type 2, any intracranial haemorrhage, any systematic bleeding and mortality at 90 days, as well as 24-hour National Institutes of Health Stroke Scale (NIHSS), early neurological improvement at 24 hours, modified Rankin Scale (mRS) shift, percentage of mRS 0-1 and mRS 0-2 at 90 days.

resultsWe identified 1113 patients with AIS who received TNK and 2360 patients who received alteplase. Following PSM, 1113 TNK-treated patients with AIS were matched to 1113 patients treated with alteplase. No significant differences were observed in rates of sICH (1.8% vs 1.98%, p=0.864) or other safety outcomes. Moreover, TNK-treated patients demonstrated a lower rate of any intracranial haemorrhage (OR: 0.51, 95% CI: 0.31 to 0.86, p=0.012). A higher proportion of patients achieving early neurological improvement at 24 hours (OR: 1.76, 95% CI: 1.48 to 2.09, p=0.000), better 90-day mRS (OR: 0.67, 95% CI: 0.57 to 0.79, p=0.000) as well as higher percentages of 90-day mRS 0-1 (OR: 1.27, 95% CI: 1.05 to 1.54, p=0.012) and mRS 0-2 (OR: 1.41, 95% CI: 1.14 to 1.75, p=0.001) compared with alteplase.

conclusionsThrombolysis with TNK is not associated with an increased risk of sICH, and may result in better early neurological improvement and 90-day functional outcomes compared with alteplase in patients with AIS.

Indexed as

Fibrinolytic AgentsIschemic StrokeTenecteplaseThrombolytic TherapyAgedAged, 80 and overChinaDisability EvaluationFemaleHumansIntracranial HemorrhagesMaleMiddle AgedRecovery of FunctionRetrospective StudiesRisk AssessmentFibrinolytic AgentsTenecteplaseTissue Plasminogen Activatorischemic strokethrombolysis

Identifiers

PMID39537238
PMCPMC12415637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.